Personalis unveils new service for cancer whole genome sequencing
Category: #health  By Pankaj Singh  Date: 2019-11-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Personalis unveils new service for cancer whole genome sequencing

 

  • The new launch of the services will help the company expand its oncology portfolio
  • Personalis has been able to sequence more than 40,000 MVP samples since 2013.

Personalis, Inc., a leading advanced genomics firm for cancer, recently unveiled its Cancer Whole Genome Sequencing that will further help the company to extend its wide cancer genomics services portfolio, that has been designed to boost the biologic insights from the given tumor samples.

Personalis’ CEO, John West commented that the new offering will help the company to provide its customers the kind of genomics solutions which provide deeper insights into the responses given by the patients to oncology therapies.

He further adds that the company is poised to offer a Cancer Whole Genome Sequencing that will combine Personalis’ technology and experience in evaluating the samples for cancer for the biopharma oncology clinical trials as well as the large scale data systems and laboratory-developed especially for the VA MVP.

Apparently, Personalis had been given a new task order earlier in 2019 under the contract with U.S. Department of Veteran Affairs (VA) especially for VA Million Veteran Program (VA MVP). This order reportedly helped bring the cumulative scale of orders that were received to date from VA MVP to more than 110,000 human genomes. Personalis expects that it will get to sequence the extra samples in the coming years as the VA gives out all of them.

Dr. Richard Chen, CSO, Personalis commented that as the company understands the complexity of the core mechanisms of cancer, the importance of analyzing wide genome structural variants as well as other types of non-coding genetic variation has considerably grown.

Chen further comments that the new service will help the company elevate its position among cancer translational researchers with other biopharma customers.   

Seemingly, the NeXT Platform by the company has been designed to adapt to the complex concept of cancer and providing its customers with data on all the 20,000 human genes, along with the immune system, through a sample of single tissue.
 

Source Credit- https://finance.yahoo.com/news/personalis-inc-expands-oncology-portfolio-223000048.html

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...

Premier to buy two Greater New York Hospital Association subsidiaries
Premier to buy two Greater New York Hospital Association subsidiaries
By Pankaj Singh

Premier Inc., a renowned healthcare improvement company, has reportedly announced that it has entered a definitive agreement to purchase certain liabilities and all the assets of Nexera, Inc. and Acurity, Inc., two wholly owned indirect subsidiaries ...

Mitsubishi creates new technology to control in-building mobile robots
Mitsubishi creates new technology to control in-building mobile robots
By Pankaj Singh

Mitsubishi Electric Corporation has recently announced its technological development to control in-building mobile robots, by using building dynamic maps. This new 3D building map will show the status of mobilities within the building, including thei...